Annie Luetkemeyer | Academic Influence

Annie Luetkemeyer's AcademicInfluence.com Rankings

Annie Luetkemeyer

Philosophy

#12159

World Rank

#16850

Historical Rank

#2356

USA Rank

Logic

#8973

World Rank

#11308

Historical Rank

#1535

USA Rank

philosophy Degrees

Download Badge

Philosophy

Annie Luetkemeyer's Degrees

Doctorate Medicine University of California, San Francisco
Masters Epidemiology University of California, Berkeley

Why Is Annie Luetkemeyer Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis. During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV.

(See a Problem?)

Annie Luetkemeyer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Remdesivir for the Treatment of Covid-19 — Final Report (2020) (4464)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (2020) (1138)
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. (2011) (557)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. (2015) (459)
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. (2015) (426)
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. (2016) (325)
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. (2014) (289)
Comparison of an Interferon-γ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals (2007) (190)
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study (2017) (141)
Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. (2006) (137)
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study (2018) (123)
Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. (2007) (118)
Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing (2020) (102)
Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. (2010) (88)
Tuberculosis Immune Reconstitution Inflammatory Syndrome in A5221 STRIDE: Timing, Severity, and Implications for HIV–TB Programs (2014) (80)
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial (2021) (75)
Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. (2016) (71)
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. (2013) (66)
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. (2011) (64)
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens (2016) (62)
Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. (2017) (59)
Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections (2019) (45)
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study (2016) (43)
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial (2022) (42)
Evaluation of Two Line Probe Assays for Rapid Detection of Mycobacterium tuberculosis, Tuberculosis (TB) Drug Resistance, and Non-TB Mycobacteria in HIV-Infected Individuals with Suspected TB (2014) (41)
Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin (2014) (38)
Tuberculosis as part of the natural history of HIV infection in developing countries. (2010) (38)
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus (2020) (34)
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. (2015) (30)
Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda (2016) (30)
IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How? (2021) (28)
Complications of HIV disease and antiretroviral therapy. (2005) (27)
Willing and able? Provision of medication for abortion by future internists. (2005) (27)
The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection (2016) (26)
Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19 (2022) (24)
Complications of HIV disease and antiretroviral therapy. (2011) (22)
Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital (2018) (22)
Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma (2022) (22)
LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study (2015) (22)
Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States. (2010) (21)
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure (2017) (21)
A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome (2019) (17)
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells (2016) (17)
Tuberculosis drug development: ensuring people living with HIV are not left behind. (2011) (16)
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. (2019) (16)
901d Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study (2015) (16)
Complications of HIV disease and antiretroviral treatment. (2010) (15)
Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification (2015) (15)
HIV-Associated Central Nervous System Tuberculosis (2014) (15)
Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection (2018) (15)
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. (2017) (15)
Localized US Efforts to Eliminate Hepatitis C. (2018) (14)
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2 (2017) (14)
Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) (2017) (14)
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses (2022) (13)
Antiretroviral therapy and TB (2006) (12)
Household ventilation and tuberculosis transmission in Kampala, Uganda. (2013) (12)
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence (2020) (12)
A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries (2016) (11)
A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries (2016) (11)
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir‐experienced, NS5A treatment‐naïve patients: Findings from two randomized trials (2018) (10)
C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT) (2016) (9)
Retrospective‐prospective study of safety and efficacy of sofosbuvir‐based direct‐acting antivirals in HIV/HCV‐coinfected participants with decompensated liver disease pre– or post–liver transplant (2020) (8)
Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV–Coinfected Adults With Persistent HBV Viremia (2011) (7)
Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial (2013) (6)
Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis (2017) (5)
O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study (2017) (5)
CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy. (2013) (5)
Pilot Study of Pioglitazone Before HCV Retreatment in HIV/HCV Genotype 1–Infected Subjects With Insulin Resistance and Previous Nonresponse to Peginterferon and Ribavirin Therapy: A5239 (2014) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences (2019) (4)
CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis. (2017) (4)
Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study (2017) (4)
HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. (2019) (4)
CROI 2019: highlights of viral hepatitis. (2019) (4)
Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. (2023) (3)
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence (2021) (3)
Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019 (2021) (3)
Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (2017) (3)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
CROI 2018: Highlights of Viral Hepatitis. (2018) (2)
CROI 2016: Viral Hepatitis and Liver Fibrosis. (2016) (2)
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. (2022) (2)
HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. (2022) (1)
Doxycycline for Sexually Transmitted Infection Prevention: Evolving Evidence and Implementation Perspectives (2021) (1)
CROI 2015: Highlights of Viral Hepatitis Therapy. (2015) (1)
CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy. (2014) (1)
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial (2023) (0)
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated (2023) (0)
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial. (2023) (0)
Clinical Presentation and Course of Acute Hepatitis C in HIV-Infected Patients (2005) (0)
pilot metabolomics study of immune reconstitution inflammatory syndrome. (2019) (0)
1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination (2022) (0)
NS 5 A treatment-naive patients : findings from two randomized trials (2017) (0)
The Role and Place of Interferon Gamma Release Assays (2007) (0)
163. High Prevalence of Urogenital and Rectal Mycoplasma genitalium in U.S. MSM with a History of STIs in the Last Year (2021) (0)
Efficacy and safety of ledipasvir/sofosbuvir, with or without ribavirin, for treatment of hepatitis C virus-mono and HCV/HIV co-infected patients who have failed prior treatment with non-NS5A, SOF-based therapies (2017) (0)
Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action (2022) (0)
Track B Clinical Science (2012) (0)
Track B Clinical Science (2012) (0)
Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR (2020) (0)
A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT) (2018) (0)
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy (2022) (0)
Epidemiology and clinical implications of atypical mycobacterial infections in cadaveric lung transplants: the role of surveillance bronchoscopy and bronchoalveolar lavage phenotype (2004) (0)
CROI 2021: Viral Hepatitis and Other Forms of Liver Injury Impacting People with HIV. (2021) (0)
Overview of Hepatitis C Virus Direct-Acting Antiviral Drugs : Present and Future (2014) (0)
Tuberculosis Associated with HIV Infection (2011) (0)
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens (2015) (0)
The HCV Cascade of Care and Improving Access to HCV Treatment (2016) (0)
448. Disproportionate Burden of COVID-19 on Latinx Residents among Hospitalized Patients at San Francisco’s Public Health Hospital (2020) (0)

This paper list is powered by the following services:

Other Resources About Annie Luetkemeyer

en.wikipedia.org

What Schools Are Affiliated With Annie Luetkemeyer?

Annie Luetkemeyer is affiliated with the following schools:

Image Attributions

Image Source for Annie Luetkemeyer